

#### KEY FEATURES (Source: Amundi Group)

**Inception date :** 17/04/2020  
**Fund structure :** SICAV under Luxembourg law  
**Directive :** UCITS IV  
**Benchmark :** 100% MSCI WORLD  
**Currency :** USD  
**Type of shares :** Capitalization  
**ISIN code :** LU1989771016  
**Bloomberg code :** CGSAAUH LX  
**Minimum recommended investment horizon :** 5 years

#### Risk Indicator (Source : Fund Admin)



Lower Risk

Higher Risk

The SRI represents the risk and return profile as presented in the Key Information Document (KID). The lowest category does not imply that there is no risk. The SRI is not guaranteed and may change over time. The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

#### KEY FIGURES (Source: Amundi Group)

**Net Asset Value (NAV) :** 150.94 ( USD )  
**Assets Under Management (AUM) :** 895.07 ( million USD )

#### KEY PEOPLE (Source: Amundi Group)

**Management company :** CPR ASSET MANAGEMENT  
**Custodian / Administrator :** CACEIS Bank, Luxembourg Branch / CACEIS Fund Administration Luxembourg

#### OPERATION & FEES (Source: Amundi Group)

**Frequency of NAV calculation :** Daily  
**Order cut-off time :** 14:00 CET Luxembourg time  
**Minimum initial subscription :** 1 Ten-Thousandth of Share(s)  
**Minimum subsequent subscription :** Nil  
**Subscription fee (max) / Redemption fee :** 5.00% / 0.00%  
**Management fees and other administrative or operating costs :** 2.31%  
**Performance fees :** No


All details are available in the legal documentation

#### INVESTMENT STRATEGY (Source: Amundi Group)

The Compartment's objective is to outperform global equity markets over the long-term period (minimum of five years) by taking advantage of the dynamics of international securities associated with the ageing of the population.

#### ANALYSIS OF THE NET PERFORMANCE (Source: Fund Admin)

##### CHANGE IN NET ASSET VALUE BASE 100 (Source: Fund Admin)



#### ANNUALISED PERFORMANCES (Source: Fund Admin) <sup>1</sup>

|                  | YTD<br>31/12/2025 | 1 month<br>31/07/2026 | 3 months<br>29/05/2026 | 1 year<br>29/08/2025 | 3 years<br>31/08/2023 | 5 years<br>31/08/2021 | Since<br>17/04/2020 |
|------------------|-------------------|-----------------------|------------------------|----------------------|-----------------------|-----------------------|---------------------|
| <b>Portfolio</b> | 3.41%             | 0.11%                 | 5.70%                  | 8.72%                | 4.95%                 | 1.82%                 | 6.26%               |
| <b>Benchmark</b> | 13.10%            | 2.58%                 | 2.36%                  | 20.37%               | 20.09%                | 11.20%                | 16.88%              |
| <b>Spread</b>    | -9.69%            | -2.47%                | 3.34%                  | -11.65%              | -15.14%               | -9.38%                | -10.62%             |

<sup>1</sup> Data corresponding to periods of more than a year are annualised.

#### Offer to Bid returns \*

|                  | YTD<br>31/12/2025 | 1 month<br>31/07/2026 | 3 months<br>29/05/2026 | 1 year<br>29/08/2025 | 3 years<br>31/08/2023 | 5 years<br>31/08/2021 | Since<br>17/04/2020 |
|------------------|-------------------|-----------------------|------------------------|----------------------|-----------------------|-----------------------|---------------------|
| <b>Portfolio</b> | -1.76%            | -4.90%                | 0.42%                  | 3.29%                | 3.17%                 | 0.78%                 | 5.41%               |

\* Offer to Bid returns include an assumed sales charge of 5%, which may or may not be charged to investors

#### ANNUAL PERFORMANCES (Source: Fund Admin) <sup>2</sup>

|                  | 2025    | 2024   | 2023    | 2022    | 2021   |
|------------------|---------|--------|---------|---------|--------|
| <b>Portfolio</b> | -4.46%  | 16.56% | 1.21%   | -8.35%  | 23.24% |
| <b>Benchmark</b> | 21.09%  | 18.67% | 23.79%  | -18.14% | 21.82% |
| <b>Spread</b>    | -25.55% | -2.11% | -22.57% | 9.79%   | 1.43%  |

<sup>2</sup> Performance varies over time and is not a reliable indication of future results. The investments are subject to market fluctuations and may gain or lose value.

#### RISK ANALYSIS (Source: Fund Admin) \*

|                                    | 1 year | 3 years | 5 years | Inception to date * |
|------------------------------------|--------|---------|---------|---------------------|
| <b>Portfolio Volatility</b>        | 9.91%  | 11.40%  | 11.89%  | 11.96%              |
| <b>Benchmark volatility</b>        | 11.40% | 12.37%  | 14.64%  | 14.47%              |
| <b>Portfolio Information ratio</b> | -1.28  | -1.65   | -0.89   | -1.08               |
| <b>Tracking Error ex-post</b>      | 9.15%  | 9.28%   | 10.56%  | 10.02%              |


\* Annualised data

EQUITY

31/08/2026

## PORTFOLIO BREAKDOWN (Source: Amundi Group)


## SECTOR BREAKDOWN (Source: Amundi Group)



## GEOGRAPHICAL BREAKDOWN (Source: Amundi Group)



## BREAKDOWN BY CURRENCY (Source: Amundi Group) \*\*



\*\* As a percentage of the assets - including currency hedging

Issuer number (excluding cash) **61**  
 Cash as % of total assets **5.42%**


## MAIN POSITIONS IN PORTFOLIO

(Source: Amundi Group) \*

|                              | Country       | Weight | Spread / Index |
|------------------------------|---------------|--------|----------------|
| APPLE INC                    | United States | 3.09%  | -2.01%         |
| BLACKROCK INC                | United States | 2.71%  | 2.53%          |
| HOYA CORP                    | Japan         | 2.60%  | 2.54%          |
| WELLTOWER INC                | United States | 2.26%  | 2.07%          |
| THERMO FISHER SCIENTIFIC INC | United States | 2.21%  | 1.96%          |
| BANK OF AMERICA CORP         | United States | 2.19%  | 1.73%          |
| ASR NEDERLAND NV             | Netherlands   | 2.12%  | 2.11%          |
| JOHNSON & JOHNSON            | United States | 2.07%  | 1.37%          |
| SERVICE CORP INTERNATIONAL   | United States | 2.05%  | 2.05%          |
| ABBVIE INC                   | United States | 1.97%  | 1.48%          |

\* Excluding mutual funds

## SECTOR ALLOCATION EVOLUTION (Source: Amundi Group)



## MANAGER'S COMMENT

On August 19, 2026, Moderna and Merck announced positive results from the Phase III INTERpath-001 trial evaluating the personalized mRNA-based cancer vaccine intismeran autogene (mRNA-4157/V940) in combination with Keytruda in patients with stage IIB–IV melanoma following complete surgical resection. The study met its primary endpoint of recurrence-free survival. A key secondary endpoint, distant metastasis-free survival, was also met, with improvements deemed statistically significant and clinically meaningful compared with Keytruda alone, and no new safety signals identified. This is the first randomized Phase III trial to demonstrate the clinical benefit of this class of “neoantigen” vaccines, representing a major validation of the mRNA platform beyond infectious disease vaccines. Detailed data have not yet been released and will be presented at an upcoming medical congress, a key step ahead of a potential regulatory filing.

August was marked by a rebound in technology stocks (+6%), as AI-related announcements renewed investor interest in the sector. Materials also rose sharply, gaining nearly 10%, supported by higher gold prices and gold-mining stocks. Conversely, pressure on bond markets weighed on the utilities and real estate sectors. Against this backdrop, the fund returned +0.1%, underperforming the MSCI World by 1.5 percentage points. This underperformance was primarily due to a structural bias, namely the absence of any exposure to technology. The lack of exposure to materials also detracted in a market driven by gold-mining stocks. Within healthcare, our significant overweight helped cushion the overall market move, although stock selection had a negative impact. Medtech stocks generally responded well to recent earnings releases, notably Alcon (+6%), Abbott (+4%) and Intuitive Surgical (+4%). Health insurers, by contrast, came under pressure, as illustrated by UnitedHealth (-6%), while medtech benefited. Pharmaceuticals also proved resilient, particularly Johnson & Johnson (+4%) and Merck (+13%) following Moderna's announcement regarding a melanoma vaccine, which also supported life sciences tools companies such as Thermo Fisher (+7%). Conversely, AstraZeneca (-4%) was affected by rumors of a merger with Bristol Myers. Finally, consumer discretionary stocks were hit by higher oil prices and rising long-term US interest rates, with cruise operators such as Royal Caribbean (-15%) and Carnival (-13%) particularly affected. In terms of portfolio activity, the main development was a net reduction in exposure to French risk. In particular, we switched out of Accor and into InterContinental in order to maintain exposure to the hotel theme while reducing country risk. Similarly, AXA was sold, notably in favor of ASR Nederland and Allianz.

Unlike August, September's monetary policy calendar will be particularly busy: the ECB will meet on September 10 and the FOMC on September 16. The tone adopted at Jackson Hole by Federal Reserve Chair Kevin Warsh, who explicitly raised the possibility of further tightening in the absence of sufficient progress in bringing inflation back toward the 2% target, together with Isabel Schnabel's warnings that inflation is unlikely to return to target at current interest-rate levels, leaves little doubt as to the restrictive stance central banks are likely to communicate. German inflation at 2.9% and the Bund yield rising to 3.32%, its highest level in fifteen years, reflect this shift in market pricing. The favorable scenario hinges on an effective de-escalation in the Strait of Hormuz and a sustained decline in Brent crude below \$80, which would allow central banks to hold back. Conversely, the adverse scenario involves continued bond-market pressure, which could further compress the valuation multiples of long-duration growth stocks—precisely the core of the fund's exposure outside financials.

At the microeconomic level, September is a transitional month between the half-year reporting season and the third-quarter earnings season. Nevertheless, several upcoming events warrant close attention. In pharmaceuticals, the FDA's ongoing review of camizestran and AstraZeneca's efforts to rebuild its cardiovascular pipeline remain the main risk factors. Meanwhile, Vyvgart's commercial momentum at argenx will determine whether the contribution recorded in August can be repeated. Carnival traditionally reports its fiscal third-quarter results at the end of September. Fuel-price trends and any potential revision to its full-year guidance will be the main areas of focus. Finally, one particularly important catalyst outside the portfolio remains the evolution of expectations for artificial intelligence capital expenditure. A further acceleration in such spending could continue to weigh on the fund's relative performance and highlights its structural vulnerability to rotations into large-cap technology stocks, to which it has very limited exposure by design.

**Important and Legal Information**

This document contains information about CPR Invest - Global Silver Age (the "Fund"), a sub-fund of CPR Invest, an undertaking for collective investment in transferable securities existing under Part I of the Luxembourg law of 17 December 2010, organised as a société anonyme and qualifies as a société d'investissement à capital variable (SICAV) registered with the Luxembourg Trade and Companies Register under number B-189.795 and having its registered office at 5, allée Scheffer, L-2520 Luxembourg. The management company of the Fund is CPR Asset Management – 91-93, Boulevard Pasteur 75015 Paris - France and the Singapore Representative of the Fund is Amundi Singapore Limited (Registration No. 198900774E), 80 Raffles Place, UOB Plaza 1, #37-01A, Singapore 048624 (CPR Asset Management and/or its affiliated companies, including without limitation Amundi Singapore Limited, being hereinafter referred to individually or jointly as "Amundi"). Amundi Singapore Limited is regulated by the Monetary Authority of Singapore.

This is a marketing communication. Investors should read the Singapore Prospectus and the Product Highlights Sheet before deciding to invest in the Fund. The share classes of the Fund available for offer to the retail public in Singapore are set out in the Singapore Prospectus and the Product Highlights Sheet, which together with the latest annual and semi-annual reports (if any) may be obtained, free of charge, at the registered office of the Singapore Representative of the Fund or at [www.amundi.com.sg](http://www.amundi.com.sg) or the Fund's authorised distributors.

This document is for information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell the Fund in any jurisdiction where such offer, solicitation or invitation would be unlawful. This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction or for the benefit of any U.S. Person (as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933 and in the Singapore Prospectus of the Fund). The Fund is not registered in the United States under the Investment Company Act of 1940 and shares of the Fund are not registered in the United States under the Securities Act of 1933. Accordingly, this document is for distribution or to be used solely in jurisdictions where it is permitted and to persons who may receive it without breaching applicable legal or regulatory requirements, or that would require the registration of Amundi or its affiliates in these countries.

**Past performance and any forecasts made are not indicative of future performance of the Fund.**

Please note that distribution/dividends (if applicable) are not guaranteed unless otherwise stated in the dividend policy for the relevant share class contained in the Singapore Prospectus. Investors should review the relevant dividends disclosure report (if applicable) found on [www.amundi.com.sg](http://www.amundi.com.sg). Any opinion or view presented is subject to change without notice. The information in this document is intended for general circulation without taking into account the specific investment objectives, financial situation or particular needs of any particular investor. An investor may wish to seek advice from a financial adviser regarding the suitability of the Fund, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before making a commitment to purchase shares in the Fund.

The Fund may invest in Additional Tier 1 and/or Tier 2 capital instruments issued by banks and insurers incorporated in Singapore, which have loss absorption features and include terms which may result in such instruments being, inter alia, partly or wholly written off, written down and/or converted to ordinary shares of the issuer upon the occurrence of a pre-defined trigger event. Trigger events are complex and difficult to predict, may be outside of the issuer's control (for example, due to regulatory action) and can result in a significant or total reduction in the value of such instruments, thereby giving rise to loss suffered by the Fund. Investors should not purchase the shares / units of the Fund if they do not understand the nature of an investment in Additional Tier 1 and/or Tier 2 capital instruments or are not comfortable with the accompanying risks. Retail investors who do not have the knowledge or experience of investing in such sophisticated products are encouraged to seek advice from a professional financial adviser. Investors should determine the suitability of an investment in the Fund in light of their own circumstances, and in particular the risk that their lack of relevant knowledge and expertise may cause them to lose all or a significant portion of the amount invested.

Where applicable and contemplated in the Singapore Prospectus, the Fund may invest in financial derivatives as part of its strategy, and a material portion of the returns may be generated from financial derivative strategies. In such scenarios, the Fund will be subject to risks associated with such investments as further detailed in the Singapore Prospectus. Additional risk factors are described in the Singapore Prospectus. Investments in the Fund are subject to investment risks, including the possible loss of the principal amount invested. Such activities may not be suitable for everyone. Value of the shares in the Fund and the income accruing to the shares, if any, may fall or rise. Any forecast, projection or target is indicative only and is not guaranteed in any way. Such information is solely indicative and may be subject to modification from time to time. References to specific securities are presented to illustrate the application of our investment philosophy only and are not to be considered recommendation by Amundi.

It is the responsibility of investors to read the legal documents in force in particular the current Singapore prospectus of the Fund. Subscriptions in the Fund will only be accepted on the basis of their latest prospectus available in English and/or the Product Highlights Sheet. A summary of information about investors' rights and collective redress mechanisms can be found in English on the regulatory page at <https://about.amundi.com/Metanav-Footer/Footer/Quick-Links/Legal-documentation>.

Information on sustainability-related aspects (if applicable) can be found at <https://about.amundi.com/Metanav-Footer/Footer/Quick-Links/Legal-documentation>.

The information contained in this document is as at the date of publication of this document except where otherwise stated. The information contained in this document has been obtained from sources believed to be reliable but has not been independently verified, although Amundi and its affiliated companies believe it to be fair and not misleading. Total percentage may not add to 100% due to rounding. Amundi does not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this document. Amundi and its associates, directors, connected parties and/or employees may from time to time have interests and or underwriting commitments in the investments mentioned in this document. Amundi does not guarantee that all risks associated to the transactions mentioned herein have been identified, nor does it provide advice as to whether you should enter into any such transaction. Amundi does not make any representation as to the merits, suitability, expected success, or profitability of any such transaction mentioned herein.

Pursuant to the new Guidelines on marketing communications under Regulation (EU) 2019/1156 of 20 June 2019 on cross-border distribution of funds issued by the European Securities and Markets Authority (ESMA), performance returns which are less than 12 months will not be reported for European domiciled funds.

**This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.**

The information contained shall not be copied, reproduced, modified, translated or distributed without the prior written approval of Amundi.